As potential alternatives for calcium phosphate bone cements, magnesium phosphate bone cements (MPC) have attracted considerable attention in recent years. However, their several defects, such as rapid setting times, highly hydration temperature and alkaline pH due to the part of the unreacted phosphate, restricted their applications in human body. With aim to overcome these defects, a novel polypeptite poly(γ‐glutamic acid) (γ‐PGA) modified MPC were developed. Effect of γ‐PGA content on the injectability, anti‐washout ability, setting times, hydration temperature, mechanical compressive strength, in vitro bioactivity and degradation were investigated. Moreover, in vitro cyto‐compatibility was evaluated using MC3T3‐E1 cells by CCK‐8 and Live/Dead staining. All these results indicated that the 10%PGA‐MPC with an improved handling performances, low hydration temperature, high mechanical compressive strength, and good cyto‐compatibility hold a great potential for bone repair and regeneration.